Do not read single calprotectin measurements in isolation when monitoring your patients with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 20, Issue 8, 2014, Pages 1416-1417

  Van Rheenen, Patrick ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; NONSTEROID ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER;

COLONOSCOPY; DISEASE ACTIVITY; DRUG USE; EDITORIAL; ENTERITIS; FECES ANALYSIS; FOLLOW UP; HUMAN; INFECTIOUS DIARRHEA; INFLAMMATORY BOWEL DISEASE; MEASUREMENT ERROR; META ANALYSIS; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SENSITIVITY AND SPECIFICITY; INFLAMMATORY BOWEL DISEASES;

BIOLOGICAL MARKERS; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX;

EID: 84905435588     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000107     Document Type: Editorial

References (4)

1. Van Rheenen PF. Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control. Inflamm Bowel Dis. 2012;18:2018-2025.
2. Lin J, Chen J, Zuo J, et al. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis. 2014;20:1407-1415.
3. Glasziou P, Irwig L, Mant D. Monitoring in chronic disease: a rational approach. BMJ. 2005;330:644-648.
4. Van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010;341:c3369.